A detailed history of Alberta Investment Management Corp transactions in Exelixis, Inc. stock. As of the latest transaction made, Alberta Investment Management Corp holds 79,000 shares of EXEL stock, worth $2.05 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
79,000
Previous 52,200 51.34%
Holding current value
$2.05 Million
Previous $1.24 Million 43.38%
% of portfolio
0.02%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$20.34 - $23.73 $545,112 - $635,964
26,800 Added 51.34%
79,000 $1.78 Million
Q3 2023

Nov 14, 2023

SELL
$19.04 - $22.74 $6 Million - $7.17 Million
-315,094 Reduced 85.79%
52,200 $1.14 Million
Q2 2023

Aug 14, 2023

SELL
$18.17 - $20.48 $341,596 - $385,024
-18,800 Reduced 4.87%
367,294 $7.02 Million
Q1 2023

May 15, 2023

BUY
$16.3 - $19.41 $2.13 Million - $2.53 Million
130,525 Added 51.07%
386,094 $7.49 Million
Q4 2022

Feb 14, 2023

BUY
$14.96 - $17.39 $1.14 Million - $1.33 Million
76,244 Added 42.52%
255,569 $4.1 Million
Q3 2022

Nov 14, 2022

BUY
$15.68 - $22.27 $49,705 - $70,595
3,170 Added 1.8%
179,325 $2.81 Million
Q2 2022

Aug 15, 2022

BUY
$17.44 - $23.16 $1.27 Million - $1.69 Million
72,864 Added 70.54%
176,155 $3.67 Million
Q1 2022

May 16, 2022

BUY
$17.03 - $22.67 $1.76 Million - $2.34 Million
103,291 New
103,291 $2.34 Million
Q4 2020

Feb 16, 2021

SELL
$18.39 - $24.8 $735,600 - $992,000
-40,000 Closed
0 $0
Q2 2020

Aug 11, 2020

BUY
$16.46 - $27.42 $658,400 - $1.1 Million
40,000 New
40,000 $950,000
Q1 2019

May 15, 2019

SELL
$19.6 - $24.76 $640,920 - $809,652
-32,700 Closed
0 $0
Q4 2018

Feb 14, 2019

BUY
$13.65 - $21.8 $290,745 - $464,340
21,300 Added 186.84%
32,700 $643,000
Q3 2018

Nov 16, 2018

SELL
$15.87 - $22.4 $185,679 - $262,079
-11,700 Reduced 50.65%
11,400 $202,000
Q2 2018

Aug 15, 2018

BUY
$18.56 - $22.45 $428,735 - $518,595
23,100 New
23,100 $497,000

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $8.35B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Alberta Investment Management Corp Portfolio

Follow Alberta Investment Management Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alberta Investment Management Corp, based on Form 13F filings with the SEC.

News

Stay updated on Alberta Investment Management Corp with notifications on news.